Skip to main content
Premium Trial:

Request an Annual Quote

BioImagene and Scimagix, Caltech, Definiens and Beecher Instruments, Galadeno and Celgene, and Serologicals


BioImagene Acquires Scimagix; Companies to Merge Image Analysis and Management

Image analysis software firm BioImagene last week said that it will acquire Scimagix, a developer of informatics systems for storing, managing, and retrieving biological images, BioInform, Inside Bioassays’ sister publication, reported last week.

Financial terms of the acquisition were not provided.

Mohan Uttarwar will serve as president and CEO of the combined company, which will operate under a new name that will be determined “some time in the next 100 days,” Uttarwar said. Robert Dunkle, CEO of Scimagix, will serve as an advisory board member for the new company.

BioImagene is located in San Jose, Calif., but is in the process of relocating to Scimagix’s larger California facility in San Mateo. Uttarwar said that no layoffs are expected due to the merger and that the combined company will employ around 60 people.

Scimagix’s flagship product, SIMS (Scientific Image Management System) allows researchers to store and query images from multiple experimental platforms. The company also sells ProteinMine, a 2D-gel analysis tool. In September, SciMagix launched CellMine HCS, an image management application for cell-based assay data.

BioImagene offers iHarness, Pathiam, and HistoGram image analysis products for diagnostic purposes such as histopathology, immunohistochemistry, and fluorescence in situ hybridization.

Uttarwar said that SIMS would be integrated with BioImagene’s iHarness platform and renamed iSIMS, BioInform reported.

Caltech Wins $25.4M Nanotechnology Grant; Systems Biology Program will Benefit

Caltech said recently that a portion of a $25.4 million grant will help fund systems biology research.

The grant, awarded by the Gordon and Betty Moore Foundation, will enable Caltech faculty to create “new nanoscale technologies to aid the emerging field commonly referred to as systems biology,” the school said in a statement on Thursday.

Caltech defines systems biology as a methodology that uses, among other components, “specific gene expression as well as ... proteins expressed by genes. In many cases, systems biology depends on advances in genomics, which in turn is based upon large-scale assays of biological activity at much smaller scales.

“Nanobiotechnology promises to provide new means for such studies, ultimately at the level of individual cells and molecules,” Caltech said.

Caltech said it will use the money for “architectural modification and creation of new laboratories, professional and administrative staff, facilities operations and service contracts, state-of-the-art research equipment, and a networking/communication program to link Caltech researchers with their peers worldwide.”

The Gordon and Betty Moore Foundation focuses on “environmental conservation, science, higher education, and the San Francisco Bay Area,” the school said. The gift is part of a $300 million commitment the foundation made to Caltech in 2001.

Definiens Agrees to Tissue Microarray Analysis Deal with Beecher Instruments

Definiens said last week that it has entered into a strategic worldwide agreement with Beecher Instruments to jointly develop automated solutions for tissue microarray image analysis.

Under the terms of the agreement, Definiens, based in Munich, Germany, will provide its Cellenger software for automated high-content analysis of tissues and cell-based assays. Beecher, located in Sun Prairie, Wisc., has used the Cellenger software to develop a suite of automated image analysis applications called TMax for use on undisclosed Beecher instruments, the companies said.

Financial terms of the deal were not disclosed.

Galadeno, Celgene Ink Target Discovery Deal

Galadeno, a unit of Galapagos Genomics, has signed a deal to provide its adenoviral siRNA and cDNA libraries, as well as its SilenceSelect and FlexSelect technologies, to Celgene for target discovery.

The terms of the multi-year deal were not disclosed.

Serologicals Forms Operating Division for Bioprocessing

Serologicals said last week that it has formed a third operating division called Celliance, which will “focus on rapidly expanding the company’s customer base and revenue growth in … bioprocessing.”

The new division is responsible for research, development, manufacturing, and commercialization of Serologicals’ cell culture supplement and diagnostic products, and contract research services through Sierra BioSource, Serologicals said in a statement.

Serologicals, based in Atlanta, Ga., is a global provider of biological products and custom services for basic research, drug discovery, development, and manufacturing. Its other two divisions are Chemicon, based in Temecula, Calif., and Upstate, which it acquired in October, based in Charlottesville, Va.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies on 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.